Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000861000 | SCV001001195 | likely benign | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Clinical Genomics, |
RCV002332753 | SCV002601701 | benign | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Mutations in HNF1A gene can predispose to MODY3. It is associated with both micro and macrovascular complications of diabetes, especially cardiovascular complications. Associated with glucosuria. May respond well to sulfonylureas. However, more evidence is required to confer the association of this particular variant rs372892932 with MODY3. | |
Ambry Genetics | RCV002332753 | SCV002739689 | uncertain significance | Maturity onset diabetes mellitus in young | 2018-12-26 | criteria provided, single submitter | clinical testing | The c.1108-4G>A intronic variant results from a G to A substitution 4 nucleotides upstream from coding exon 6 in the HNF1A gene. This nucleotide position is poorly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is not predicted to have any significant effect on this splice acceptor site; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002501189 | SCV002807375 | likely benign | Diabetes mellitus type 1; Type 1 diabetes mellitus 20; Maturity-onset diabetes of the young type 3; Type 2 diabetes mellitus; Hepatic adenomas, familial; Nonpapillary renal cell carcinoma | 2021-07-21 | criteria provided, single submitter | clinical testing |